SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, will announce its financial results for the second quarter ended June 30, 2009 on Thursday, August 6, 2009 after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific time.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen’s lead combination product candidates targeted for obesity are Contrave(R), which completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010, and Empatic(TM) which is in the later stages of Phase 2 clinical development. Both product candidates take advantage of the Company’s understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
CONTACT: Graham Cooper, Chief Financial Officer of Orexigen,
+1-858-875-8600; or Lori Rosen of WeissComm Partners, +1-212-301-7173, for
Orexigen
Web site: http://www.orexigen.com/
